Can you stop taking Methylprednisolone after 1 day?
By
Dr Natalia Marceli Stephanes (PhD)
Author bio
Dr Natália Marcéli Stephanes PhD is a Pharmacist with expertise in Drugs Administration and Toxicity; Discovery of New Drugs; Cancer Treatment; Biochemical Analyzes and Hematological Analyzes. She writes and reviews content on these topics.
Dr Natália Marcéli Stephanes’ Highlights:
- Pharmacist at the Department of Health of Santa Catarina State, Brazil
- PhD with a focus on oncology treatment
- Years of experience in commercial pharmacy
- Bachelor, Master and PhD degrees in Pharmacy at the Federal University of Santa Catarina
Professional Experience:
From her undergraduate studies to her Master’s and Doctorate degrees in Pharmacy, Dr Natália Marcéli Stephanes has participated in numerous scientific studies in the field of oncology and onco-hematology at the University Hospital of the Federal University of Santa Catarina, Brazil. Her research has focused on understanding the molecular and biochemical bases of malignant neoplasms and investigating safer and more effective therapeutic alternatives.
Dr Natália Marcéli Stephanes has also served as an assistant professor of haematology for undergraduate students at the Federal University of Santa Catarina. Additionally, she held the position of professor of Hospital Pharmacy at the Qualificar Technical School in Brazil, where she developed instructional materials for use in the Pharmacy Postgraduate Program at the Leonardo Da Vinci University Center.
In addition to her academic experiences, Dr Natália Marcéli Stephanes possesses a strong expertise in commercial pharmacy, with in-depth knowledge of medications, their routes of administration, desired effects, adverse effects, and toxicity.
Currently, Dr Natália Marcéli Stephanes works as a Pharmacist at the Health Department of Santa Catarina State, where her role entails providing pharmaceutical scientific consulting services to judges.
Education:
- 2016 Bachelor in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2018 Master in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2023 PhD in Pharmacy at the Federal University of Santa Catarina, Brazil
The main publications of Dr Natália Marcéli Stephanes are:
Falchetti M ; Delgobo M, Zancanaro H, Almeida K, Das Neves RN, Dos Santos B, Stefanes NM, et al. Bishop Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing. Comput. Biol. Med [Internet]. 2023; 152:106347.
Feuser PM, Matos dos Santos PC, Cordeiro AP, Stefanes NM, Walter LO, Maioral MF, Santos-Silva MC, et al. Antineoplastic activity of free 4-nitrochalcone and encapsulated in poly(thioether-ester) nanoparticles obtained by thiol-ene polymerization in two human leukemia cell lines (Jurkat and K562). J Drug Deliv Sci Technol [Internet]. 2022; 67:102924.
Jacques AV, Stefanes NM, Walter LO, Perondi DM, Efe FL, Souza LFS, Sens L, et al. Synthesis of chalcones derived from 1-naphthylacetophenone and evaluation of their cytotoxic and apoptotic effects in acute leukemia cell lines. Bioorg. Chem [Internet]. 2021; 116:105315.
Duarte BF, Vieira DSC, Lisboa ML, Stefanes NM, Grando LJ, Santos-Silva MC. Características clínico-epidemiológicas de pacientes portadores de carcinoma de células escamosas de boca. Arquivos Catarinenses de Medicina. 2021; 50(2): 232–245.
Machado V, Jacques AV, Stefanes NM, Santos-Silva MC, Biavatti MW. Anti-leukemic activity of semisynthetic derivatives of Lupeol. Nat. Prod. Res. 2021; 35(22):4494-4501.
Bigolin A, Maioral MF, Stefanes NM, Mascarello A, Chiaradia-Delatorre LD, Nunes RJ, Yunes RA, et al. A novel sulfonamide derivative as a strong and selective apoptotic agent against hematological malignancies. Chem. Pap. 2020; 74:2965–2976.
Bigolin A, Maioral MF, Stefanes NM, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Cytotoxic mechanisms of primin, a natural quinone isolated from Eugenia hiemalis, on hematological cancer cell lines. Anticancer Drugs. 2020; 31(7):709-717.
Maioral MF, Stefanes NM, Neufeldt PD, Chiaradia-Delatorre LD, Nunes RJ, Santos-Silva MC. Aldehyde biphenyl chalcones induce immunogenic apoptotic-like cell death and are promising new safe compounds against a wide range of hematologic cancers. Future Med. Chem. 2020; 12(8):673–688.
Perondi DM, Jacques AV, Stefanes NM, Maioral MF, Sens L, Pacheco LA, Cury NM, et al. A novel thiosemicarbazone as a promising effective and selective compound for acute leukemia. Anticancer Drugs. 2019; 30(8):p 828-837.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Argenta DF, Dotto MER, Santos-Silva MC, et al. PEO-chitosan nanofibers containing carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanoparticles loaded with pyrazoline for skin cancer treatment. Eur. Polym. J. 2019; 119:335-343.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Santos-Silva MC, Nunes RJ, Parize AL, et al. A new and efficient carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanocarrier for a pyrazoline with antileukemic activity. Mater. Sci. Eng. C [Internet]. 2019; 105:110051.
Maioral MF, Stefanes NM, Bigolin A, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Miconidine acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells. Invest. New Drugs. 2019; 37:912–922.
Srefanes NM, Toigo J, Maioral MF, Jacques AV, Chiaradia-Delatorre LD, Perondi DM, Ribeiro AAB, et al. Synthesis of novel pyrazoline derivatives and the evaluation of death mechanisms involved in their antileukemic activity. Bioorg. Med. Chem. 2019; 27(2):375-382.
Maioral MF, Bodack CN, Stefanes NM, Bigolin A, Mascarello A, Chiaradia-Delatorre LD, Yunes RA, et al. Cytotoxic effect of a novel naphthylchalcone against multiple cancer cells focusing on hematologic malignancies. Biochim. 2017; 140:48-57.
You can view some of Dr Natália’s work below and links to her professional profile below.
Research Gate: https://www.researchgate.net/profile/Natalia-Stephanes
Linkedin: https://www.linkedin.com/in/nataliamarceli/
Can you stop taking Methylprednisolone after 1 day?
It is not recommended to stop taking Methylprednisolone after one day unless you have a valid reason to stop the medication – like an allergic reaction or unbearable side effects (1).
Methylprednisolone is an anti-inflammatory medication and is definitely no magic pill that can cure your illness after just one dose. You need to give the medication some time to see a noticeable or acceptable difference in your symptoms (1).
If you experience any side effects or concerns after taking Methylprednisolone for one day, it’s crucial to communicate with your healthcare provider. They will provide you with appropriate guidance and may adjust your treatment plan accordingly.
Some people could be allergic to Methylprednisolone and the drug should not be continued in such people because of potential health risks.
Potential risks of stopping Methylprednisolone after 1 day without having a valid reason
If you stop taking Methylprednisolone after just one day without a valid reason, it can have negative impacts on your treatment goals. Doing so can disrupt the intended therapeutic effects.
One day of use may not lead to physical dependence, but it can still interfere with the effectiveness of the treatment. Methylprednisolone needs time to build up in your system and exert its anti-inflammatory actions. By discontinuing it early, you may not give the drug sufficient time to work effectively (1,2).
Moreover, the underlying medical condition that Methylprednisolone was prescribed to manage may not be adequately addressed. The inflammation may persist or worsen, leading to ongoing symptoms and potentially delaying your recovery.
Inconsistent use of Methylprednisolone can also impact your doctor’s ability to manage your response to the medication accurately. They may have difficulty evaluating its effectiveness and may need to adjust the treatment plan based on incomplete information.
To ensure the best outcomes from Methylprednisolone or any other prescribed medication, it’s essential to follow your healthcare provider’s instructions properly. If you have concerns about the medication or experience side effects, it’s crucial to communicate openly with your healthcare provider.
Alternative treatment strategies for people who’re allergic to Methylprednisolone
If someone is allergic to Methylprednisolone or cannot tolerate the medication, there are alternative treatment strategies that their healthcare provider may consider based on their specific health condition. Some of these alternatives may include:
- Non-steroidal anti-inflammatory drugs (NSAIDs): NSAIDs are medications that can help reduce inflammation and pain. They work differently from corticosteroids and can be used for various conditions, such as arthritis, muscle pain, or certain skin conditions (3).
- Antihistamines: Antihistamines are commonly used to manage allergy symptoms. They block the effects of histamine, a chemical released during an allergic reaction, and can relieve symptoms like sneezing, itching, and runny nose (4).
- Immunomodulators: Immunomodulators are medications that can help regulate the immune system and reduce inflammation in certain conditions like autoimmune disorders (5).
- Topical treatments: For skin conditions or localized inflammation, topical treatments like creams or ointments containing non-steroidal ingredients can be used to provide relief without systemic exposure.
- Physical therapies: In some cases, physical therapies like physiotherapy or occupational therapy may be recommended to manage pain and improve mobility.
- Lifestyle changes: Making lifestyle changes, such as adopting a healthy diet, getting regular exercise, and managing stress, can also support overall health and well-being.
It’s crucial for individuals to work closely with their healthcare provider to find the most appropriate alternative treatment that suits their specific medical conditions and individual needs.
Was this helpful?
References
1.-
Ocejo A, Correa R. Methylprednisolone. 2022 Dec 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 31335060. https://www.ncbi.nlm.nih.gov/books/NBK544340
2.-
LABEL: METHYLPREDNISOLONE- methylprednisolone tablet. DailyMed [Internet]. Available from: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61&type=pdf
3.-
Ghlichloo I, Gerriets V. Nonsteroidal Anti-inflammatory Drugs (NSAIDs). 2023 May 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 31613522. https://www.ncbi.nlm.nih.gov/books/NBK547742
4.-
Farzam K, Sabir S, O’Rourke MC. Antihistamines. 2022 Dec 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 30844215. https://www.ncbi.nlm.nih.gov/books/NBK538188
5.-
Lebish IJ, Moraski RM. Mechanisms of immunomodulation by drugs. Toxicol Pathol. 1987;15(3):338-45. doi: 10.1177/019262338701500312. PMID: 3317771. https://pubmed.ncbi.nlm.nih.gov/3317771/
